Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 3/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | UGCG | Q16739 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751394 | 0.89 | CXCR5 (0.46) | CXCR5PSMB5FABP4PTGER4UGCG | |
| SCHEMBL5751771 | 0.88 | CXCR5 (0.47) | CXCR5PSMB5FABP4PTGER4UGCG | |
| SCHEMBL2138756 | 0.86 | MAPK14 (0.40) | CXCR5MAPK14PTGER4UGCGLTA4H | |
| SCHEMBL1898861 | 0.83 | CXCR5 (0.47) | CXCR5PSMB5FABP4PTGER4UGCG | |
| SCHEMBL5752196 | 0.79 | MAPK14 (0.55) | MAPK14LTA4HEPHX2MEN1KMT2A | |
| SCHEMBL5752254 | 0.79 | MAPK14 (0.48) | MAPK14LTA4HEPHX2MEN1KMT2A | |
| SCHEMBL1901979 | 0.78 | CTSL (0.40) | CXCR5PSMB5UGCGCTSL | |
| SCHEMBL1899579 | 0.78 | CTSL (0.40) | CXCR5PSMB5UGCGCTSL | |
| SCHEMBL1900536 | 0.78 | PSMB5 (0.48) | CXCR5PSMB5PTGER4UGCGCTSL | |
| SCHEMBL1898616 | 0.77 | CTSL (0.44) | CXCR5PSMB5PTGER4UGCGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CXCR5 3335/4885PSMB5 470/4885MAPK14 4138/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CXCR5 3335/4885PSMB5 470/4885MAPK14 4138/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CXCR5 3681/4885PSMB5 3173/4885MAPK14 3101/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | CXCR5 3335/4885PSMB5 470/4885MAPK14 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.